Jump to content

Cannabis Science

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Bri (talk | contribs) at 22:57, 11 April 2024 (added Category:Cannabis companies of the United States using HotCat). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Cannabis Science Inc.
Company typePrivate
IndustryPharmaceutical
Founded2000 (as National Healthcare Technology), reestablished in 2009
HeadquartersIrvine, California, U.S.
Key people
Raymond C. Dabney (President, CEO, Co-Founder and Director)
Robert Melamede
(Co-Founder)[1]
ProductsPharmaceutical products
Websitecannabisscience.com

Cannabis Science, Inc. is a biotech company based in Irvine, California. The company was incorporated in 2009 and formerly traded under the ticker CBIS on the Over-The-Counter Bulletin Board until October 2019, when their SEC license was revoked.[2]

The company's stated goal was to obtain Food and Drug Administration (FDA) approval for cannabis-based medicines, with a focus on treating skin cancer (basal and squamous cell carcinomas),[3] posttraumatic stress disorder[4] and HIV.[3] The FDA has not approved these treatments.[5]

References

  1. ^ Radford, Bill (April 9, 2010). "Company looks to create cannabis-based medicines". The Gazette. Retrieved 2019-06-19.
  2. ^ Mayani, Mamta. "Cannabis Science enters transition stage as shares halted". Seeking Alpha. Retrieved 5 March 2020.
  3. ^ a b "Cannabis Science Appoints Former GlaxoSmithKline Global Director of HIV Research Dorothy Bray, Ph.D., to Scientific Advisory Board Focusing on CS-TATI-1 and Other Emerging Scientific Investigations". Cannabisscience.com. 2012-06-14. Retrieved 2012-07-04.
  4. ^ Fine, Doug (August 3, 2012). Too High to Fail: Cannabis and the New Green Economic Revolution. Penguin. p. 8. ISBN 978-1101588895.
  5. ^ "קנאביס רפואי". Tuesday, 16 March 2021